SU-E-T-634: Pre-Verification of FFF Prostate VMAT Plans with Gamma Method and DVHs Reconstructed Based On Measurements with 2D-ARRAY (PTW 1500) and OCTAVIUS 4D
Purpose: The aim of this work was to characterize the clinical correctness of FFF prostate treatment VMAT plans based on analysis of DVHs reconstructed from pre-verification 2D-arrays measurements. Methods: The new 2D ion chamber array 1500 with rotational phantom cylindrical Octavius 4D and Verisoft 6.1 software with DVH option (PTW, Freiburg) were used to determine the clinical usefulness of the treatment plans. Ten patients treated with VMAT high-fractionated (2 fraction x 7,5 Gy) FFF prostate plans (TrueBeam, Varian) were analyzed using the 3D gamma analysis by local dose method with a 5% threshold for various tolerance parameters DTA [mm] and DD [%] were 1%/1, 2%/2, 3%/3. Additional, based on the measurements of irradiation dose distributions and patients’ CT scans with contoured structures of organs, the DVHs were reconstructed using a software. The obtained DVHs were compared to planned dose distributions and the deviations were analysed with parameters: for CTV D50, D98, D2, and D25, D50, Dmax for OARs — rectum, bladder and left/right femoral heads. Results: The analyzed treatment plans passed gamma criteria (3/3%; 95%), the results obtained were as follow: mean value and standard deviation of gamma score for criteria (DTA[mm]/DD[%]): 1/1% (L53.3±3.2); 2/2% (L87.0±2.2); 3/3% (L97.5±0.9). In the DVH analysis, the highest differences were observed for OARs (especially for bladder): the mean percentage differences values for rectum, bladder and left/right femoral heads were: D25 (1.67; 6.83)%, D50 (0.18; 7.18; 1.53; 0.30)%, Dmax (−0.84; −1.64; 0.37; −4.63)%, respectively. For the CTV mean relative deviations for proper parameters were in good agreement with TPS: D98 (0.95±2.21)%, D50 (1.93±0.67)%, D2 (1.76±0.76)%. Conclusion: The gamma method is recommended tool for pre-verification analysis of correctness of treatment plans. Moreover, the scrutiny checking with reconstructed DVH gives additional, clinical information about quality of plan, especially about coverage of CTV and sparing of health tissues.
- OSTI ID:
- 22538143
- Journal Information:
- Medical Physics, Vol. 42, Issue 6; Other Information: (c) 2015 American Association of Physicists in Medicine; Country of input: International Atomic Energy Agency (IAEA); ISSN 0094-2405
- Country of Publication:
- United States
- Language:
- English
Similar Records
SU-E-T-641: Development and Verification of Automatic Reading Dose of Interest From Eclipse's DVH
SU-E-T-417: The Impact of Normal Tissue Constraints On PTV Dose Homogeneity for Intensity Modulated Radiotherapy (IMRT), Volume Modulated Arc Therapy (VMAT) and Tomotherapy